Xvivo Financial Statements From 2010 to 2024
| XVIPF Stock | USD 41.23 0.77 1.83% |
Check Xvivo Perfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xvivo Perfusion's main balance sheet or income statement drivers, such as , as well as many indicators such as . Xvivo financial statements analysis is a perfect complement when working with Xvivo Perfusion Valuation or Volatility modules.
Xvivo |
Xvivo Perfusion AB Company Shares Owned By Insiders Analysis
Xvivo Perfusion's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Xvivo Perfusion Shares Owned By Insiders | 12.25 % |
Most of Xvivo Perfusion's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xvivo Perfusion AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 12.25% of Xvivo Perfusion AB are shares owned by insiders. This is 19.3% lower than that of the Healthcare sector and 21.22% lower than that of the Medical Devices industry. The shares owned by insiders for all United States stocks is 21.41% lower than that of the firm.
Xvivo Perfusion AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Xvivo Perfusion's current stock value. Our valuation model uses many indicators to compare Xvivo Perfusion value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Xvivo Perfusion competition to find correlations between indicators driving Xvivo Perfusion's intrinsic value. More Info.Xvivo Perfusion AB is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Xvivo Perfusion AB is roughly 2.39 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Xvivo Perfusion's earnings, one of the primary drivers of an investment's value.About Xvivo Perfusion Financial Statements
Xvivo Perfusion stakeholders use historical fundamental indicators, such as Xvivo Perfusion's revenue or net income, to determine how well the company is positioned to perform in the future. Although Xvivo Perfusion investors may analyze each financial statement separately, they are all interrelated. For example, changes in Xvivo Perfusion's assets and liabilities are reflected in the revenues and expenses on Xvivo Perfusion's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Xvivo Perfusion AB. Please read more on our technical analysis and fundamental analysis pages.
Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 115 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.